Minimally Invasive Salvage Prostatectomy after Primary Radiation or Ablation Treatment.

To analyze oncologic, functional and morbidity outcomes for patients undergoing minimally invasive salvage prostatectomy (MISP) at our institution.

Between 2001-2015, 5841 patients underwent radical prostatectomy at our institution, out of which 28 were MISP. Indications for MISP were PSA nadir + 2ng/dl in radio-recurrent patients and biopsy-proven PCa in other ablative treatments. We analyzed primary cancer characteristics, surgical data, perioperative complications, oncologic and functional outcomes of MISP, and further compared results between MISP after primary whole-gland (WT) and focal (FT) treatments.

Median age at salvage treatment was 65 (IQR 61-68). Compared to WT, MISP after FT had significantly lower operative time (133 vs. 176 min, p=0,001) and fewer upstaging (≥pT3a) (28% vs. 79%, p=0,008) at final pathology. Overall, PSM were noted in 4 patients (14%). Perioperative complications were observed in 9 patients with no difference between groups. At 12-months follow-up, 57% were continent and 33% had moderate to severe urinary leak. Potency was preserved in 6 out of 10 pre-operatively potent patients. Over a median follow-up of 62 months (IQR 43-110), 11 patients relapsed with a median time to BCR of 16 months (IQR 7-25). Recurrences were managed with salvage radiotherapy in 6 patients, 4 with hormone therapy and 1 CRPC. Overall, 24 patients are alive at last follow-up and 18 (72%) remain disease free.

MISP after primary radiation / ablation for PCa is feasible, safe with acceptable oncological outcomes. Compared to FT, MISP after WT appears to have longer operative time and more frequent upstaging.

Urology. 2016 May 03 [Epub ahead of print]

Estefania Linares Espinós, Rafael Sánchez-Salas, Arjun Sivaraman, Jose I Perez-Reggeti, Eric Barret, Francois Rozet, Marc Galiano, Dominique Prapotnich, Xavier Cathelineau

Department of Urology. Institut Montsouris, Université Paris-Descartes. Paris, France., Department of Urology. Institut Montsouris, Université Paris-Descartes. Paris, France.. Electronic address: ., Department of Urology. Institut Montsouris, Université Paris-Descartes. Paris, France., Department of Urology. Institut Montsouris, Université Paris-Descartes. Paris, France., Department of Urology. Institut Montsouris, Université Paris-Descartes. Paris, France., Department of Urology. Institut Montsouris, Université Paris-Descartes. Paris, France., Department of Urology. Institut Montsouris, Université Paris-Descartes. Paris, France., Department of Urology. Institut Montsouris, Université Paris-Descartes. Paris, France., Department of Urology. Institut Montsouris, Université Paris-Descartes. Paris, France.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe